This publication summarises data from REDES and REALITI-A, two real-world studies evaluating the effectiveness and safety of mepolizumab for the treatment of severe eosinophilic asthma. Two-year follow-up data from REALITI-A are included. This publication has been commissioned and funded by GSK. The content is based on published studies and the author’s opinions and may not reflect the views of GSK. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. All trademarks mentioned in this review are the property of their respective owners.
Please login below to download this issue (PDF)